Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study of OTO-104 in Subjects With Meniere's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria includes, but is not limited to:~* Subject has a diagnosis of definite unilateral Meniere's disease.~* Subject agrees to maintain their current standard of care treatments for Meniere's disease while on-study.~Exclusion Criteria includes, but is not limited to:~* Subject has an infection in the ear, sinuses, or upper respiratory system.~* Subject is pregnant or lactating.~* Subject has a history of immunodeficiency disease.~* Subject has active or recent (\<1 month prior to screening) middle ear disease, including but not limited to: chronic otitis media, acute otitis media, middle ear effusions, middle ear atelectasis, or cholesteatoma.~* Subject has experienced an adverse reaction to intratympanic injection of steroids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- OTO-104 (Type: EXPERIMENTAL): 12 mg dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).